From Looksmaxxing to FDA Approval? The U.S. Considers Greenlighting Mystery Peptides FDA Peptide Reclassification 2026: What Researchers Want BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved The FDA just changed the game for peptides. April 2026 The FDA is reviewing Category 2 peptides for potential removal from restricted status. Full approval for some peptides may be